Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.
750mcg – 2.5 mgSubQ2x/week
Thymosin Beta-4 (TB4) is a naturally occurring 43-amino acid peptide that is the most abundant member of the beta-thymosin family. Originally isolated from the thymus gland by Allan Goldstein in the 1960s-70s, TB4 is now known to be expressed in virtually all nucleated cells throughout the body. It is the primary intracellular G-actin sequestering peptide, playing a fundamental role in actin cytoskeleton dynamics, cell motility, and tissue repair.
Quick Start
Route
Subcutaneous (SubQ)
Start low
750mcg SubQ
Frequency
2x/week
Timing
No specific requirement
Same timing as TB-500. Any time of day, no fasting required.
❋
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Tiered Protocols · lowest first
Conservative start
750mcg · Subcutaneous (SubQ) · 2x/week
conservative starter
750mcg
2x/week
Intermediate
Full Chain Systemic Repair
2.5 mg · SubQ · 2x Weekly
anecdotal · Community convention. Human trials exist for the molecule but used IV and topical routes: NCT00382174, NCT00832091, NCT02597803.
True 43-amino acid chain. Elicits broader cellular repair pathways than truncated TB-500 fragments. This is the best human-evidenced peptide in its class. Note the trials delivered it topically or intravenously rather than subcutaneously, and several were stopped early for business reasons rather than for safety. IMPORTANT: the human trials of thymosin beta-4 do NOT support this dose by this route. They used INTRAVENOUS and TOPICAL administration (pressure and venous ulcers, dry eye) at doses far removed from a 2.5 mg subcutaneous injection. This subcutaneous figure is community convention. Smart 2007 is a mouse cardiac model.
2.5 mg
2x Weekly
Reconstitution CalculatorU-100
050100u
Draw to
— units
◆
◆
◆
01
How it works
Sequesters G-actin monomers to regulate actin polymerization, controlling cytoskeletal dynamics essential for cell migration, wound closure, and tissue remodeling. The N-terminal tetrapeptide Ac-SDKP has potent anti-inflammatory and anti-fibrotic properties.
Promotes angiogenesis by upregulating VEGF and stimulating endothelial cell migration and tube formation. Also activates cardiac progenitor cells and promotes cardiomyocyte survival after ischemic injury via Akt/PI3K signaling pathway.
Reduces inflammation by downregulating NF-kB-mediated inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) and promotes anti-inflammatory macrophage (M2) polarization. Inhibits apoptosis in damaged cells via activation of survival signaling pathways.
02
What to expect
Early
Days 1–7
Days 1-7: Anti-inflammatory effects begin. Reduced pain and swelling at injury sites. Cellular migration and early angiogenesis initiated.
03
Evidence
HumanPresent
AnimalStrong
In-vitroPresent
Each reference below was re-fetched from its PubMed record, and the quoted sentence was
confirmed to appear in that abstract and to support the claim it sits under. Follow any of
them to read the source.
Exact-molecule evidence boundary: the live abstract reports the quoted finding for Thymosin Beta-4 Full; no broader inference is made.
In this study, we investigated whether the angiogenic thymic peptide thymosin beta4 (Tbeta4) enhanced wound healing in a rat full thickness wound model.
Evidence scope. Exact molecule wording appears in the quoted live sentence. Only the population/model, formulation, route, and outcome expressly stated there are supported.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the
same as saying they are false — it marks where the evidence is missing.
Dose/route: 750mcg; Subcutaneous (SubQ); 2x/week. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
04
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Thymosin Alpha-1Different thymosin family members - TB4 for tissue repair, TA-1 for immune modulation. Non-conflicting
IpamorelinGH secretagogue and tissue repair peptide support recovery through independent pathways
N-Acetyl Selank AmidateAnxiolytic peptide and tissue repair peptide have no pharmacological interaction
KPVAnti-inflammatory tripeptide and tissue repair peptide address different aspects of healing
Keep separate
GHK-CuCopper-peptide can oxidize methionine residue in TB4 full-length sequence, potentially reducing bioactivity - do not mix in same syringe
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
05
Pharmacokinetics
Illustrative plasma concentration · 11 h
Half-life
~2-3 hours
Peak · Tmax
~30-60 min
SubQ
Elimination
~10-15 hours
Bioavailability
~90-100%
SubQ
Duration of action
4-7 days
Actin regulation, cell migration, and tissue repair effects persist well beyond plasma clearance
Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 14-28 days. Protect from light.
06
Regulatory status
Not FDA-approved. Investigational new drug for corneal wound healing (RGN-259). Research compound for all other applications. WADA prohibited substance.
Put it to work
Calculate, log & track
Open Thymosin Beta-4 Full straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.